Source 1primary paper2025MED
Toolkit/Deep Brain Stimulation
Deep Brain Stimulation
Also known as: DBS
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Deep brain stimulation (DBS) is an established neuromodulation method used as an add-on treatment for severe Parkinson's disease and other chronic neurological conditions. In the cited review, DBS is presented primarily as the clinical benchmark for comparison with optogenetic neuromodulation.
Usefulness & Problems
Why this is useful
DBS is useful as a clinically accepted neuromodulation approach for severe Parkinson's disease and other chronic neurological disorders. The supplied evidence supports its role as an existing therapeutic standard against which newer, more selective neuromodulation strategies are evaluated.
Problem solved
DBS addresses the need for neuromodulation in severe Parkinson's disease and other chronic neurological conditions. The evidence does not provide more specific details on the targeted symptoms, circuits, or stimulation paradigms.
Problem links
addresses the need for more effective treatment options for opioid and stimulant use disorders
LiteratureThe article frames emerging neuromodulation approaches, especially deep brain stimulation, as relevant because current treatment options remain insufficient for these disorders.
Source:
The article frames emerging neuromodulation approaches, especially deep brain stimulation, as relevant because current treatment options remain insufficient for these disorders.
allows optimization of the therapeutic window while minimizing adverse effects
LiteratureIt addresses disabling tremor in patients for whom pharmacological treatment is insufficient. The adjustability is framed as helping optimize benefit while reducing adverse effects.
Source:
It addresses disabling tremor in patients for whom pharmacological treatment is insufficient. The adjustability is framed as helping optimize benefit while reducing adverse effects.
alternative brain stimulation approach for comparison with optogenetics
LiteratureIt is treated as an alternative neuromodulation strategy against which optogenetics is compared. The provided text does not support more detailed claims.
Source:
It is treated as an alternative neuromodulation strategy against which optogenetics is compared. The provided text does not support more detailed claims.
Improves motor symptoms in Parkinson's disease
LiteratureIt addresses Parkinson's disease motor symptoms and is framed as the most established neurosurgical option. This positions it as an alternative when pharmacological treatment is limited by side effects or fluctuations.
Source:
It addresses Parkinson's disease motor symptoms and is framed as the most established neurosurgical option. This positions it as an alternative when pharmacological treatment is limited by side effects or fluctuations.
provides a circuit-targeted therapeutic modulation approach in humans
LiteratureIt offers a way to act on reward-circuit dysfunction in humans after preclinical studies identified relevant circuitry.
Source:
It offers a way to act on reward-circuit dysfunction in humans after preclinical studies identified relevant circuitry.
provides a clinically usable neuromodulation approach where optogenetics is not yet clinically applicable
LiteratureIt provides a clinically deployable way to modulate neural circuits in movement and psychiatric-related disorders. This makes it the practical therapeutic endpoint discussed in the review.
Source:
It provides a clinically deployable way to modulate neural circuits in movement and psychiatric-related disorders. This makes it the practical therapeutic endpoint discussed in the review.
provides a neuromodulation modality considered as an alternative treatment strategy for chronic insomnia
LiteratureIt is discussed as a possible biologically informed intervention strategy for chronic insomnia.
Source:
It is discussed as a possible biologically informed intervention strategy for chronic insomnia.
provides an invasive neuromodulation modality considered for treatment of neurological disease and AD
LiteratureIt is presented as a way to modulate neural circuits in attempts to treat AD-related dysfunction.
Source:
It is presented as a way to modulate neural circuits in attempts to treat AD-related dysfunction.
provides an invasive route for manipulating cerebellar circuitry
LiteratureIt offers an invasive option for circuit-level neuromodulation when cerebellar stimulation is being considered as therapy.
Source:
It offers an invasive option for circuit-level neuromodulation when cerebellar stimulation is being considered as therapy.
provides a non-genetic approach for modulating neural activity
LiteratureIt addresses the need to modulate neural activity without relying on genetic methods.
Source:
It addresses the need to modulate neural activity without relying on genetic methods.
provides a putative treatment option for treatment-resistant depression
LiteratureIt is intended to address depression that has remained resistant to prior treatment. The review summarizes clinically relevant antidepressant effects in a subset of studied patients.
Source:
It is intended to address depression that has remained resistant to prior treatment. The review summarizes clinically relevant antidepressant effects in a subset of studied patients.
provides a surgical option when pharmacological treatments provide insufficient relief
LiteratureIt addresses disabling tremor in patients for whom pharmacological treatment is insufficient. The adjustability is framed as helping optimize benefit while reducing adverse effects.
Source:
It addresses disabling tremor in patients for whom pharmacological treatment is insufficient. The adjustability is framed as helping optimize benefit while reducing adverse effects.
provides a treatment option for patients with drug-resistant epilepsy
LiteratureIt offers a therapeutic option for patients whose epilepsy is resistant to drugs. The review frames it as a way to control seizure generators initiating epileptic activities.
Source:
It offers a therapeutic option for patients whose epilepsy is resistant to drugs. The review frames it as a way to control seizure generators initiating epileptic activities.
provides a viable treatment option for epilepsy when medication is refractory
LiteratureIt addresses the need for treatment options in medically refractory epilepsy. The review presents DBS as a viable option for seizure control in this setting.
Source:
It addresses the need for treatment options in medically refractory epilepsy. The review presents DBS as a viable option for seizure control in this setting.
provides a way to modulate brain activity in clinical practice
LiteratureIt offers a practical route for focused modulation of brain activity in disorders with dysfunctional neural activity.
Source:
It offers a practical route for focused modulation of brain activity in disorders with dysfunctional neural activity.
provides treatment option for refractory Parkinson's disease, essential tremor, and dystonia
LiteratureIt addresses symptoms in movement disorders that are pharmacologically refractory.
Source:
It addresses symptoms in movement disorders that are pharmacologically refractory.
Published Workflows
Objective: To investigate the current research status, key topics, and future trends in neuromodulation technology over the past decade using bibliometric visualization tools.
Why it works: The workflow combines a defined literature corpus from Web of Science with complementary visualization analyses: VOSviewer for countries, institutions, authors and keywords, and CiteSpace for co-cited references, keyword clusters and bursts.
literature retrieval from Web of ScienceVOSviewer analysisCiteSpace analysis
Stages
- 1.Literature retrieval from Web of Science(selection)
This stage defines the literature corpus to be analyzed.
Selection: Relevant literature in the field of neuromodulation technology published in Web of Science from January 1, 2014 to June 18, 2024
- 3.CiteSpace visualization analysis(secondary_characterization)
This stage extracts co-citation structure and burst signals to identify clusters and emerging frontiers.
Selection: Visualization analysis of co-cited references, keyword clusters and bursts
Steps
- 1.Retrieve relevant neuromodulation literature from Web of Science
Assemble the literature corpus covering January 1, 2014 to June 18, 2024 for downstream bibliometric analysis.
A defined literature set is required before visualization tools can be applied.
- 2.Import retrieved literature into CiteSpace and VOSvieweranalysis software
Prepare the retrieved literature corpus for visualization analyses in both software tools.
Import into the analysis platforms is needed before running software-specific bibliometric analyses.
- 3.Analyze countries, institutions, authors, and keywords with VOSvieweranalysis software
Characterize publication output patterns and keyword structure in the neuromodulation literature set.
Once the corpus is imported, VOSviewer can be used for actor- and keyword-level mapping.
- 4.Analyze co-cited references, keyword clusters, and keyword bursts with CiteSpaceanalysis software
Identify co-citation structure, topic clusters, and emerging burst terms in the neuromodulation literature set.
After corpus import, CiteSpace is used to extract cluster and burst signals that inform hotspot and frontier interpretation.
Objective: Systematically identify and qualitatively synthesize evidence on optogenetics in animal models of chronic neurodegenerative diseases, while comparing the modality with deep brain stimulation and DREADD techniques.
Why it works: The review uses a structured search and screening process to narrow a larger literature set to studies suitable for qualitative analysis, then synthesizes disease-specific findings and limitations.
PRISMA-guided literature searchrisk-of-bias assessmentqualitative evidence synthesiscross-modality comparison
Stages
- 1.Literature search(in_silico_filter)
To comprehensively identify candidate articles for the systematic review.
Selection: Search strategy performed based on PRISMA guidelines.
- 2.Suitability screening for qualitative analysis(decision_gate)
To narrow the initial literature set to studies that meet the review's inclusion logic for synthesis.
Selection: Studies deemed suitable for qualitative analysis.
- 3.Risk-of-bias assessment(secondary_characterization)
To characterize the quality and bias profile of the included animal studies before or during synthesis.
Selection: Risk of bias assessed following the Systematic Review Centre for Laboratory Animal Experimentation tool.
- 4.Qualitative synthesis and cross-modality comparison(functional_characterization)
To summarize disease-specific findings, identify areas with limited evidence, and frame optogenetics relative to alternative neuromodulation approaches.
Selection: Qualitative analysis of included studies and comparison with deep brain stimulation and DREADD techniques.
Objective: To provide a comprehensive and systematic review of closed-loop BCI research across brain stimulation modalities and assess their potential to improve quality of life in neurological and psychiatric disorders.
Why it works: The review uses defined criteria to shortlist studies from research databases and then organizes them into stimulation categories to compare evidence across modalities.
closed-loop interpretation of neuronal electrical signalsfeedback-driven brain stimulationdefined-criteria literature shortlistingcategorization of studies by stimulation modality
Stages
- 1.Study shortlisting from research databases(selection)
To narrow the literature to studies meeting the authors' defined review criteria before analysis.
Selection: defined criteria applied to studies from well-known research databases
- 2.Categorization by brain stimulation technique(hit_picking)
To organize shortlisted studies into comparable stimulation modality groups for downstream analysis.
Selection: assignment of shortlisted studies into brain stimulation technique categories
- 3.Analysis of shortlisted studies(secondary_characterization)
To synthesize what the shortlisted literature shows about benefits of closed-loop BCI and where coverage remains inadequate.
Selection: analysis of the shortlisted study set to assess benefits and literature gaps
Steps
- 1.Apply defined criteria to studies from well-known research databases
To identify which studies should be shortlisted for the review.
The literature must be narrowed before studies can be categorized and analyzed.
- 2.Group shortlisted studies into stimulation technique categories
To organize the shortlisted literature by modality for structured comparison.
Categorization follows shortlisting so that only included studies are organized for analysis.
- 3.Analyze the 76 shortlisted studies for benefits and coverage gaps
To synthesize evidence for functional improvement and identify undercovered application areas.
Analysis is performed after shortlisting and categorization so the final corpus is defined and organized.
Optogenetically-inspired neuromodulation: Translating basic discoveries into therapeutic strategies
2021Objective: Use preclinical optogenetic perturbation studies to identify circuit targets and stimulation paradigms that can inform improved DBS therapies for movement and compulsive disorders.
Why it works: The abstract states that optogenetics provides selective and temporally precise control of defined circuits, allowing investigators to reverse-engineer DBS mechanisms and derive rational circuit targets and stimulation paradigms.
selective activation of defined neural circuitsselective inhibition of defined neural circuitsmodulation of neural circuit functioninduction of plasticity within defined basal ganglia circuitsoptogenetic circuit perturbationbehavioral evaluationDBS protocol inspiration
Stages
- 1.Preclinical optogenetic circuit interrogation(functional_characterization)
This stage exists to identify how defined circuits and plasticity mechanisms contribute to motor and compulsive behaviors before attempting therapeutic protocol optimization.
Selection: Use optogenetic tools to selectively activate, inhibit, or modulate genetically defined neural circuits and test their roles in maladaptive behaviors.
- 2.Mechanistic reverse-engineering of DBS(secondary_characterization)
The abstract states that DBS optimization is difficult because mechanisms are poorly understood, so a mechanistic reverse-engineering stage helps explain therapeutic effects.
Selection: Leverage optogenetic findings to infer mechanisms underlying therapeutic DBS effects in movement and compulsive disorders.
- 3.DBS protocol inspiration and optimization(decision_gate)
The review frames the translational value of optogenetics as inspiring novel DBS protocols rather than direct clinical optogenetic use.
Selection: Prioritize DBS targets and stimulation paradigms that are supported by optogenetic evidence for ameliorating specific behavioral symptoms or compensating for pathological synaptic plasticity.
Objective: Structured literature review to identify and compare deep brain stimulation targets for treatment of drug-resistant epilepsy.
Why it works: The review searches major biomedical databases, selects studies assessing seizure-frequency impact in drug-resistant epilepsy, and synthesizes evidence across meta-analyses, randomized controlled trials, and observational studies to compare DBS targets.
database literature searchstudy selectionevidence synthesis across study designs
Stages
- 1.Literature search in Medline and PubMed(in_silico_filter)
To gather the candidate literature base for subsequent evidence selection and synthesis.
Selection: Structured review of literature from 1980 to 2018 using Medline and PubMed.
- 2.Selection of studies assessing seizure-frequency impact in DRE(decision_gate)
To narrow the literature to studies directly relevant to the review's clinical question.
Selection: Articles assessing the impact of deep brain stimulation on seizure frequency in patients with drug-resistant epilepsy were selected.
- 3.Inclusion of meta-analyses, randomized controlled trials, and observational studies(functional_characterization)
To synthesize evidence from multiple study designs when comparing DBS targets.
Selection: Meta-analyses, randomized controlled trials, and observational studies were included.
Steps
- 1.Search Medline and PubMed for DBS literature from 1980 to 2018
Assemble the review corpus for DBS in drug-resistant epilepsy.
The literature base must be gathered before applying outcome-based selection criteria.
- 2.Select articles that assess seizure-frequency impact in patients with drug-resistant epilepsy
Restrict the corpus to studies directly relevant to the review endpoint and patient population.
Outcome- and population-based filtering follows the broad database search to remove less relevant literature.
- 3.Synthesize evidence across included study designs
Compare DBS targets using evidence from meta-analyses, randomized trials, and observational studies.
Study-design synthesis occurs after relevant articles have been selected.
Objective: Establish DBS as a viable treatment option for epilepsy by integrating circuit understanding, precise targeting methods, and rigorous clinical trial design.
Why it works: The review states that better understanding of epileptogenic networks, precise stereotactic techniques, and rigorous trial design combined to improve evidence quality and make DBS viable for epilepsy.
neuromodulationseizure controlepileptogenic network targetingprecise stereotactic techniquesrigorous trial design
Stages
- 1.Epileptogenic network understanding(in_silico_filter)
The abstract indicates that improved understanding of epileptogenic networks was one of the factors that improved evidence quality for DBS in epilepsy.
Selection: better understanding of epileptogenic networks
- 2.Precise stereotactic targeting(functional_characterization)
The abstract identifies precise stereotactic techniques as a key contributor to improved evidence quality and DBS viability.
Selection: precise stereotactic techniques
- 3.Rigorous clinical trial evaluation(confirmatory_validation)
The abstract states that rigorous trial design improved the quality of available evidence and helped make DBS a viable treatment option.
Selection: rigorous trial design and published clinical evidence
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Target processes
translationInput: Light
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationimplementation constraint: payload burdenimplementation constraint: spectral hardware requirementoperating role: delivery
The provided evidence does not describe device architecture, electrode placement, stimulation parameters, or surgical workflow for DBS. The mention of viral vector gene transfer pertains to optogenetic translation rather than DBS implementation itself.
The review states that current DBS is limited by relatively coarse neuromodulation compared with the prospective cell-type and structure selectivity of optogenetic approaches. The supplied evidence does not describe additional limitations such as surgical burden, adverse effects, or parameter constraints.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2review2017Frontiers in Neuroscience
Source 3review2019The Cerebellum
Source 4primary paper2026MED
Source 5review2019Frontiers in Neurology
Source 6review2014Neurotherapeutics
Source 7review2014Neuropsychopharmacology
Source 8primary paper2025MED
Source 9primary paper2025MED
Source 10review2025MED
Source 11primary paper2025MED
Source 12review2022Frontiers in Neuroscience
Source 13review2021International review of neurobiology
Source 14review2024Journal of Neuroscience Research
Source 15review2017Neurotherapeutics
Source 16review2025MED
Ranked Claims
Deep brain stimulation offers adjustable parameters that allow optimization of the therapeutic window while minimizing adverse effects.
DBS offers the advantage of adjustable parameters, allowing optimization of the therapeutic window while minimizing adverse effects.
Deep brain stimulation, radiofrequency thalamotomy, magnetic resonance-guided focused ultrasound, and Gamma Knife radiosurgery demonstrate comparable efficacy for essential tremor and other tremor-inducing syndromes according to this review.
These techniques demonstrate comparable efficacy.
Neuromodulation techniques have shown significant advancements in treating neurological and psychiatric disorders.
The article discusses new and emerging neuromodulation approaches for opioid and stimulant use disorders, with particular focus on deep brain stimulation.
This article provides an overview of the current standard of care for opioid use disorder and stimulant use disorder. New and emerging neuromodulation approaches with a particular focus on deep brain stimulation are then discussed.
Deep brain stimulation provides substantial symptom relief and medication reduction but is invasive and carries surgical and hardware-related risks.
The review categorizes neuromodulation techniques into genetic methods and non-genetic methods.
AAV2-hAADC has shown early-phase safety and efficacy in Parkinson's disease but remains in early clinical stages.
ProSavin has shown early-phase safety and efficacy in Parkinson's disease but remains in early clinical stages.
DBS and MRgFUS differ significantly in mechanism, adaptability, safety profile, and long-term efficacy.
The review comparatively analyzes biophysical, genetic, and biological neuromodulation approaches with emphasis on molecular targets and translational potential.
The reviewed neuromodulation methods were assessed based on specificity, safety, reversibility, and mechanistic clarity.
Across newer neurosurgical and gene therapy approaches for Parkinson's disease, larger-scale controlled trials are still required to establish long-term safety and efficacy.
Future large-scale controlled trials are needed to further optimize therapeutic strategies involving DBS and MRgFUS.
Deep brain stimulation is the most established neurosurgical technique for Parkinson's disease and has strong evidence for improving motor symptoms.
Focused ultrasound provides a noninvasive option for Parkinson's disease, but most related studies lack long-term data.
A critical gap in commonly used neuromodulation methods is incomplete mechanistic understanding, and identifying molecular targets may improve therapeutic precision.
Fully harnessing the therapeutic potential of neuromodulation requires integration and innovation in technologies, optimization of delivery methods, improvement of mediums, and evaluation of toxicity.
Botulinum neurotoxins provide long-lasting yet reversible inhibition through well-characterized molecular pathways but require stereotaxic injections and remain invasive.
Biophysical neuromodulation methods are widely used in clinical practice but often rely on empirical outcomes because their molecular targets are undefined.
Magnetic resonance-guided focused ultrasound is a non-invasive neuromodulation alternative that provides incisionless lesioning for selected cases, particularly tremor-dominant phenotypes.
Genetic neuromodulation tools offer cell-type precision in experimental systems but face translational barriers related to delivery and safety.
The article proposes neuromodulation approaches targeting the dorsal raphe nucleus as a novel treatment strategy for chronic insomnia.
Our objective in the current article is to provide a conceptual model for the exploitation of neuromodulation approaches targeting the DRN as a novel treatment strategy for chronic insomnia.
Deep brain stimulation is a cornerstone treatment for pharmacologically refractory Parkinson's disease, essential tremor, and dystonia.
DRN-targeted interventions may offer personalized, biologically informed treatments for individuals with chronic insomnia.
discusses how DRN-targeted interventions may offer personalized, biologically informed treatments for individuals with chronic insomnia.
DBS and MRgFUS have complementary roles that support individualized, data-driven treatment approaches.
The review includes nanovectors, magnetic nanoparticles, and quantum dots as nanotechnology approaches relevant to Alzheimer's disease diagnosis or treatment.
The review includes optogenetics, photobiomodulation, electrical stimulation, ultrasound stimulation, and magnetic neurostimulation as neurostimulation modalities relevant to Alzheimer's disease.
Optogenetics and deep brain stimulation are described as neurotechnological tools used not only to study the brain but also for treatment applications in neurological disease.
Deep brain stimulation is the only clinical treatment mentioned in the abstract that can achieve circuit-specific neuromodulation in psychiatric contexts.
The mechanisms underlying the therapeutic effects of DBS for psychiatric disorders are poorly understood, making optimization difficult.
Optogenetic studies can be leveraged to reverse-engineer DBS mechanisms and inspire novel DBS protocols by identifying circuit targets and stimulation paradigms.
The reviewed DBS literature for drug-resistant epilepsy includes evidence from animal experiments and humans across multiple neural targets.
To date, deep brain stimulation of various neural targets has been investigated in animal experiments and humans.
The supplied evidence scaffold identifies TMS, rTMS, tDCS/ctDCS, theta burst stimulation, DBS, and CBI as explicit named methods or readouts relevant to the review's cerebellar neurostimulation landscape.
Explicitly supported component/tool names in the discovered sources include transcranial magnetic stimulation (TMS), repetitive TMS (rTMS), transcranial direct current stimulation (tDCS/ctDCS), theta burst stimulation, deep brain stimulation (DBS), and cerebellar brain inhibition (CBI).
The review covers both invasive and non-invasive approaches for manipulating cerebellar circuits in humans and animal models.
We report on the most advanced techniques for manipulating cerebellar circuits in humans and animal models and define key hurdles and questions for moving forward.
Deep brain stimulation is presented as a treatment option for patients with drug-resistant epilepsy.
Deep brain stimulation for seizures may be an option in patients with drug-resistant epilepsy.
The review states that current deep brain stimulation is limited by relatively coarse neuromodulation, whereas optogenetics offers the prospect of more selective action on physiological structures when target cells are made light sensitive.
the current practice of DBS is hampered by the relatively coarse level of neuromodulation achieved. Optogenetics, in contrast, offers the perspective of much more selective actions on the various physiological structures, provided that the stimulated cells are rendered sensitive to the action of light.
The review states that current deep brain stimulation is limited by relatively coarse neuromodulation, whereas optogenetics offers the prospect of more selective action on physiological structures when target cells are made light sensitive.
the current practice of DBS is hampered by the relatively coarse level of neuromodulation achieved. Optogenetics, in contrast, offers the perspective of much more selective actions on the various physiological structures, provided that the stimulated cells are rendered sensitive to the action of light.
The review states that current deep brain stimulation is limited by relatively coarse neuromodulation, whereas optogenetics offers the prospect of more selective action on physiological structures when target cells are made light sensitive.
the current practice of DBS is hampered by the relatively coarse level of neuromodulation achieved. Optogenetics, in contrast, offers the perspective of much more selective actions on the various physiological structures, provided that the stimulated cells are rendered sensitive to the action of light.
The review states that current deep brain stimulation is limited by relatively coarse neuromodulation, whereas optogenetics offers the prospect of more selective action on physiological structures when target cells are made light sensitive.
the current practice of DBS is hampered by the relatively coarse level of neuromodulation achieved. Optogenetics, in contrast, offers the perspective of much more selective actions on the various physiological structures, provided that the stimulated cells are rendered sensitive to the action of light.
The review states that current deep brain stimulation is limited by relatively coarse neuromodulation, whereas optogenetics offers the prospect of more selective action on physiological structures when target cells are made light sensitive.
the current practice of DBS is hampered by the relatively coarse level of neuromodulation achieved. Optogenetics, in contrast, offers the perspective of much more selective actions on the various physiological structures, provided that the stimulated cells are rendered sensitive to the action of light.
The review states that current deep brain stimulation is limited by relatively coarse neuromodulation, whereas optogenetics offers the prospect of more selective action on physiological structures when target cells are made light sensitive.
the current practice of DBS is hampered by the relatively coarse level of neuromodulation achieved. Optogenetics, in contrast, offers the perspective of much more selective actions on the various physiological structures, provided that the stimulated cells are rendered sensitive to the action of light.
The review states that current deep brain stimulation is limited by relatively coarse neuromodulation, whereas optogenetics offers the prospect of more selective action on physiological structures when target cells are made light sensitive.
the current practice of DBS is hampered by the relatively coarse level of neuromodulation achieved. Optogenetics, in contrast, offers the perspective of much more selective actions on the various physiological structures, provided that the stimulated cells are rendered sensitive to the action of light.
The review states that recent advances in viral vector gene transfer have substantially reduced vector-associated cytotoxicity and immune responses, supporting possible clinical translation of optogenetic neuromodulation.
Recent advancements of viral vector technology for gene transfer substantially reduce vector-associated cytotoxicity and immune responses. This brings about the possibility to transfer this technology into the clinic as a possible alternative to DBS and neuromodulation.
The review states that recent advances in viral vector gene transfer have substantially reduced vector-associated cytotoxicity and immune responses, supporting possible clinical translation of optogenetic neuromodulation.
Recent advancements of viral vector technology for gene transfer substantially reduce vector-associated cytotoxicity and immune responses. This brings about the possibility to transfer this technology into the clinic as a possible alternative to DBS and neuromodulation.
The review states that recent advances in viral vector gene transfer have substantially reduced vector-associated cytotoxicity and immune responses, supporting possible clinical translation of optogenetic neuromodulation.
Recent advancements of viral vector technology for gene transfer substantially reduce vector-associated cytotoxicity and immune responses. This brings about the possibility to transfer this technology into the clinic as a possible alternative to DBS and neuromodulation.
The review states that recent advances in viral vector gene transfer have substantially reduced vector-associated cytotoxicity and immune responses, supporting possible clinical translation of optogenetic neuromodulation.
Recent advancements of viral vector technology for gene transfer substantially reduce vector-associated cytotoxicity and immune responses. This brings about the possibility to transfer this technology into the clinic as a possible alternative to DBS and neuromodulation.
The review states that recent advances in viral vector gene transfer have substantially reduced vector-associated cytotoxicity and immune responses, supporting possible clinical translation of optogenetic neuromodulation.
Recent advancements of viral vector technology for gene transfer substantially reduce vector-associated cytotoxicity and immune responses. This brings about the possibility to transfer this technology into the clinic as a possible alternative to DBS and neuromodulation.
The review states that recent advances in viral vector gene transfer have substantially reduced vector-associated cytotoxicity and immune responses, supporting possible clinical translation of optogenetic neuromodulation.
Recent advancements of viral vector technology for gene transfer substantially reduce vector-associated cytotoxicity and immune responses. This brings about the possibility to transfer this technology into the clinic as a possible alternative to DBS and neuromodulation.
The review states that recent advances in viral vector gene transfer have substantially reduced vector-associated cytotoxicity and immune responses, supporting possible clinical translation of optogenetic neuromodulation.
Recent advancements of viral vector technology for gene transfer substantially reduce vector-associated cytotoxicity and immune responses. This brings about the possibility to transfer this technology into the clinic as a possible alternative to DBS and neuromodulation.
Insights from preclinical rodent reward-circuit studies are being translated into the clinic through pilot transcranial magnetic stimulation and deep brain stimulation therapies for human cocaine dependence.
these insights from preclinical rodent work are now being translated into the clinic, where transcranial magnetic simulation and deep brain stimulation therapies are being piloted in human cocaine dependence
Deep brain stimulation is being increasingly applied to neurologic and psychiatric disorders including medically refractory epilepsy.
As a result, it is being increasingly applied to a range of neurologic and psychiatric disorders, including medically refractory epilepsy.
Several uncontrolled DBS studies in small treatment-resistant depression cohorts across different target regions reported clinically relevant antidepressant effects in about half of patients.
reported responder fraction about half of the patients
Improved understanding of epileptogenic networks, precise stereotactic techniques, and rigorous trial design have improved evidence quality and made DBS a viable treatment option for epilepsy.
only recently have better understanding of epileptogenic networks, precise stereotactic techniques, and rigorous trial design combined to improve the quality of available evidence and make DBS a viable treatment option.
For DBS in epilepsy, underlying mechanisms, anatomical targets, and stimulation parameters remain areas of active investigation.
Nonetheless, underlying mechanisms, anatomical targets, and stimulation parameters remain areas of active investigation.
DBS research in treatment-resistant depression needs better animal models, larger sample sizes, long-term follow-up, and blinded sham-controlled designs to draw final conclusions on efficacy and side effects.
DBS procedures for depression are associated with surgical risks such as hemorrhage, psychiatric complications such as suicidal attenuation and hypomania, and high costs.
Deep brain stimulation has proven remarkably safe and effective in the treatment of movement disorders.
Deep brain stimulation (DBS) has proven remarkably safe and effective in the treatment of movement disorders.
DBS targeting the medial forebrain bundle was reported to yield promising antidepressant results within a few days of stimulation and at lower stimulation intensities.
Approval Evidence
16 sources36 linked approval claimsfirst-pass slug deep-brain-stimulation
This review summarizes the current evidence on surgical therapies, including deep brain stimulation (DBS)... DBS offers the advantage of adjustable parameters, allowing optimization of the therapeutic window while minimizing adverse effects.
Source:
This review categorizes neuromodulation techniques into non-genetic neuromodulation methods (including deep brain stimulation...)
Source:
Deep brain stimulation (DBS) has been a cornerstone treatment for pharmacologically refractory Parkinson's disease, essential tremor, and dystonia for over three decades.
Source:
New and emerging neuromodulation approaches with a particular focus on deep brain stimulation are then discussed.
Source:
The review incorporates data from both preclinical and clinical studies covering deep brain stimulation...
Source:
presents current methodologies for neuromodulation approaches (including transcranial magnetic stimulation, focused ultrasound, and deep brain stimulation paradigms)
Source:
Deep brain stimulation (DBS) is the most established neurosurgical technique, and has strong evidence that it can improve motor symptoms.
Source:
Our study aimed to review systematically the findings of optogenetics and its potential applications in animal models of chronic neurodegenerative diseases and compare it with deep brain stimulation and designer receptors exclusively activated by designer drugs techniques.
Source:
Neurotechnological approaches, including optogenetics and deep brain stimulation, have exploded as new tools for not only the study of the brain but also for application in the treatment of neurological diseases.
Source:
To date, deep brain stimulation (DBS) is the only clinical treatment that can be used to achieve circuit-specific neuromodulation in the context of psychiatric.
Source:
Explicitly supported component/tool names in the discovered sources include transcranial magnetic stimulation (TMS), repetitive TMS (rTMS), transcranial direct current stimulation (tDCS/ctDCS), theta burst stimulation, deep brain stimulation (DBS), and cerebellar brain inhibition (CBI).
Source:
Deep brain stimulation is a safe and effective neurointerventional technique... The aim of this review is to present the targets of the deep brain stimulation for the treatment of drug-resistant epilepsy.
Source:
advantage statementsupports
Deep brain stimulation offers adjustable parameters that allow optimization of the therapeutic window while minimizing adverse effects.
DBS offers the advantage of adjustable parameters, allowing optimization of the therapeutic window while minimizing adverse effects.
Source:
comparative efficacysupports
Deep brain stimulation, radiofrequency thalamotomy, magnetic resonance-guided focused ultrasound, and Gamma Knife radiosurgery demonstrate comparable efficacy for essential tremor and other tremor-inducing syndromes according to this review.
These techniques demonstrate comparable efficacy.
Source:
application statementsupports
Neuromodulation techniques have shown significant advancements in treating neurological and psychiatric disorders.
Source:
article scopesupports
The article discusses new and emerging neuromodulation approaches for opioid and stimulant use disorders, with particular focus on deep brain stimulation.
This article provides an overview of the current standard of care for opioid use disorder and stimulant use disorder. New and emerging neuromodulation approaches with a particular focus on deep brain stimulation are then discussed.
Source:
benefit and risksupports
Deep brain stimulation provides substantial symptom relief and medication reduction but is invasive and carries surgical and hardware-related risks.
Source:
categorizationsupports
The review categorizes neuromodulation techniques into genetic methods and non-genetic methods.
Source:
comparative modalitysupports
DBS and MRgFUS differ significantly in mechanism, adaptability, safety profile, and long-term efficacy.
Source:
comparative review scopesupports
The review comparatively analyzes biophysical, genetic, and biological neuromodulation approaches with emphasis on molecular targets and translational potential.
Source:
evaluation axessupports
The reviewed neuromodulation methods were assessed based on specificity, safety, reversibility, and mechanistic clarity.
Source:
evidence gapsupports
Future large-scale controlled trials are needed to further optimize therapeutic strategies involving DBS and MRgFUS.
Source:
evidence statussupports
Deep brain stimulation is the most established neurosurgical technique for Parkinson's disease and has strong evidence for improving motor symptoms.
Source:
field gapsupports
A critical gap in commonly used neuromodulation methods is incomplete mechanistic understanding, and identifying molecular targets may improve therapeutic precision.
Source:
field needsupports
Fully harnessing the therapeutic potential of neuromodulation requires integration and innovation in technologies, optimization of delivery methods, improvement of mediums, and evaluation of toxicity.
Source:
mechanistic limitationsupports
Biophysical neuromodulation methods are widely used in clinical practice but often rely on empirical outcomes because their molecular targets are undefined.
Source:
therapeutic conceptsupports
The article proposes neuromodulation approaches targeting the dorsal raphe nucleus as a novel treatment strategy for chronic insomnia.
Our objective in the current article is to provide a conceptual model for the exploitation of neuromodulation approaches targeting the DRN as a novel treatment strategy for chronic insomnia.
Source:
therapeutic rolesupports
Deep brain stimulation is a cornerstone treatment for pharmacologically refractory Parkinson's disease, essential tremor, and dystonia.
Source:
treatment positioningsupports
DRN-targeted interventions may offer personalized, biologically informed treatments for individuals with chronic insomnia.
discusses how DRN-targeted interventions may offer personalized, biologically informed treatments for individuals with chronic insomnia.
Source:
treatment strategysupports
DBS and MRgFUS have complementary roles that support individualized, data-driven treatment approaches.
Source:
tool application scopesupports
Optogenetics and deep brain stimulation are described as neurotechnological tools used not only to study the brain but also for treatment applications in neurological disease.
Source:
clinical modality statussupports
Deep brain stimulation is the only clinical treatment mentioned in the abstract that can achieve circuit-specific neuromodulation in psychiatric contexts.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts DBS with RF thalamotomy, MRgFUS, and GKSR as other surgical options with comparable efficacy.; The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.; The abstract lists transcranial magnetic stimulation and focused ultrasound as other neuromodulation approaches, and also notes CBT-I and medications as standard treatments.; The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.; MRgFUS is presented as a non-invasive alternative with different mechanism, adaptability, safety profile, and long-term efficacy.; The abstract explicitly places deep brain stimulation alongside optogenetics and DREADD techniques as comparison modalities.; The review places DBS alongside optogenetics and non-invasive stimulation modalities such as photobiomodulation, electrical, ultrasound, and magnetic stimulation.; Optogenetics is discussed as a preclinical alternative for mechanistic dissection and protocol inspiration, but not as a current clinical substitute.; The abstract contrasts different DBS targets rather than different non-DBS modalities. It names anterior and centromedian thalamic nuclei, hippocampus, basal ganglia, cerebellum, and hypothalamus as alternative target sites within DBS.; Nearby alternatives in the supplied evidence are non-invasive cerebellar stimulation approaches such as TMS, rTMS, tDCS, and theta burst stimulation.; The abstract names transcranial magnetic stimulation as a contrasted stimulation-based alternative.; The abstract contrasts different DBS target regions rather than non-DBS alternatives. It specifically highlights medial forebrain bundle stimulation as a notable target within the broader DBS approach.; The review also discusses cortical and deep neuromodulation more broadly. The supplied web summary identifies responsive neurostimulation as an adjacent comparator modality explicitly cited by the review.
Source:
The abstract contrasts DBS with RF thalamotomy, MRgFUS, and GKSR as other surgical options with comparable efficacy.
Source:
The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.
Source:
The abstract lists transcranial magnetic stimulation and focused ultrasound as other neuromodulation approaches, and also notes CBT-I and medications as standard treatments.
Source:
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Source:
MRgFUS is presented as a non-invasive alternative with different mechanism, adaptability, safety profile, and long-term efficacy.
Source:
The abstract explicitly places deep brain stimulation alongside optogenetics and DREADD techniques as comparison modalities.
Source:
The review places DBS alongside optogenetics and non-invasive stimulation modalities such as photobiomodulation, electrical, ultrasound, and magnetic stimulation.
Source:
Optogenetics is discussed as a preclinical alternative for mechanistic dissection and protocol inspiration, but not as a current clinical substitute.
Source:
The abstract contrasts different DBS targets rather than different non-DBS modalities. It names anterior and centromedian thalamic nuclei, hippocampus, basal ganglia, cerebellum, and hypothalamus as alternative target sites within DBS.
Source:
Nearby alternatives in the supplied evidence are non-invasive cerebellar stimulation approaches such as TMS, rTMS, tDCS, and theta burst stimulation.
Source:
The abstract names transcranial magnetic stimulation as a contrasted stimulation-based alternative.
Source:
The abstract contrasts different DBS target regions rather than non-DBS alternatives. It specifically highlights medial forebrain bundle stimulation as a notable target within the broader DBS approach.
Source:
The review also discusses cortical and deep neuromodulation more broadly. The supplied web summary identifies responsive neurostimulation as an adjacent comparator modality explicitly cited by the review.
Source-backed strengths
The cited evidence states that DBS has evolved into a well-accepted add-on treatment, indicating established clinical use. Its main strength in this evidence set is its status as a recognized therapeutic benchmark in neuromodulation.
Source:
the current practice of DBS is hampered by the relatively coarse level of neuromodulation achieved. Optogenetics, in contrast, offers the perspective of much more selective actions on the various physiological structures, provided that the stimulated cells are rendered sensitive to the action of light.
Compared with AAV2-hAADC
The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.
Compared with brain stimulation
The abstract explicitly places deep brain stimulation alongside optogenetics and DREADD techniques as comparison modalities.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The abstract explicitly places deep brain stimulation alongside optogenetics and DREADD techniques as comparison modalities.
Compared with chemogenetics
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Compared with focused ultrasound
The abstract contrasts DBS with RF thalamotomy, MRgFUS, and GKSR as other surgical options with comparable efficacy.; The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.; The abstract lists transcranial magnetic stimulation and focused ultrasound as other neuromodulation approaches, and also notes CBT-I and medications as standard treatments.; The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.; MRgFUS is presented as a non-invasive alternative with different mechanism, adaptability, safety profile, and long-term efficacy.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The abstract contrasts DBS with RF thalamotomy, MRgFUS, and GKSR as other surgical options with comparable efficacy.
Source:
The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.
Source:
The abstract lists transcranial magnetic stimulation and focused ultrasound as other neuromodulation approaches, and also notes CBT-I and medications as standard treatments.
Source:
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Source:
MRgFUS is presented as a non-invasive alternative with different mechanism, adaptability, safety profile, and long-term efficacy.
Compared with gene therapy
The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.
Compared with magnetic resonance-guided focused ultrasound thalamotomy
The abstract contrasts DBS with RF thalamotomy, MRgFUS, and GKSR as other surgical options with comparable efficacy.; MRgFUS is presented as a non-invasive alternative with different mechanism, adaptability, safety profile, and long-term efficacy.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The abstract contrasts DBS with RF thalamotomy, MRgFUS, and GKSR as other surgical options with comparable efficacy.
Source:
MRgFUS is presented as a non-invasive alternative with different mechanism, adaptability, safety profile, and long-term efficacy.
Compared with magnetogenetics
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Compared with MR-guided focused ultrasound
The abstract contrasts DBS with RF thalamotomy, MRgFUS, and GKSR as other surgical options with comparable efficacy.; MRgFUS is presented as a non-invasive alternative with different mechanism, adaptability, safety profile, and long-term efficacy.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The abstract contrasts DBS with RF thalamotomy, MRgFUS, and GKSR as other surgical options with comparable efficacy.
Source:
MRgFUS is presented as a non-invasive alternative with different mechanism, adaptability, safety profile, and long-term efficacy.
Compared with optogenetic functional interrogation
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.; The abstract explicitly places deep brain stimulation alongside optogenetics and DREADD techniques as comparison modalities.; The review places DBS alongside optogenetics and non-invasive stimulation modalities such as photobiomodulation, electrical, ultrasound, and magnetic stimulation.; Optogenetics is discussed as a preclinical alternative for mechanistic dissection and protocol inspiration, but not as a current clinical substitute.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Source:
The abstract explicitly places deep brain stimulation alongside optogenetics and DREADD techniques as comparison modalities.
Source:
The review places DBS alongside optogenetics and non-invasive stimulation modalities such as photobiomodulation, electrical, ultrasound, and magnetic stimulation.
Source:
Optogenetics is discussed as a preclinical alternative for mechanistic dissection and protocol inspiration, but not as a current clinical substitute.
Compared with optogenetic membrane potential perturbation
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.; The abstract explicitly places deep brain stimulation alongside optogenetics and DREADD techniques as comparison modalities.; The review places DBS alongside optogenetics and non-invasive stimulation modalities such as photobiomodulation, electrical, ultrasound, and magnetic stimulation.; Optogenetics is discussed as a preclinical alternative for mechanistic dissection and protocol inspiration, but not as a current clinical substitute.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Source:
The abstract explicitly places deep brain stimulation alongside optogenetics and DREADD techniques as comparison modalities.
Source:
The review places DBS alongside optogenetics and non-invasive stimulation modalities such as photobiomodulation, electrical, ultrasound, and magnetic stimulation.
Source:
Optogenetics is discussed as a preclinical alternative for mechanistic dissection and protocol inspiration, but not as a current clinical substitute.
Compared with ProSavin
The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.
Compared with toxin-based neuromodulation
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Nearby alternatives in the supplied evidence are non-invasive cerebellar stimulation approaches such as TMS, rTMS, tDCS, and theta burst stimulation.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
Nearby alternatives in the supplied evidence are non-invasive cerebellar stimulation approaches such as TMS, rTMS, tDCS, and theta burst stimulation.
Compared with transcranial electrical and magnetic stimulation
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
The abstract lists transcranial magnetic stimulation and focused ultrasound as other neuromodulation approaches, and also notes CBT-I and medications as standard treatments.; The abstract names transcranial magnetic stimulation as a contrasted stimulation-based alternative.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The abstract lists transcranial magnetic stimulation and focused ultrasound as other neuromodulation approaches, and also notes CBT-I and medications as standard treatments.
Source:
The abstract names transcranial magnetic stimulation as a contrasted stimulation-based alternative.
Compared with ultrasonography
The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.; The abstract lists transcranial magnetic stimulation and focused ultrasound as other neuromodulation approaches, and also notes CBT-I and medications as standard treatments.; The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.; The review places DBS alongside optogenetics and non-invasive stimulation modalities such as photobiomodulation, electrical, ultrasound, and magnetic stimulation.
Shared frame: source-stated alternative in extracted literature
Strengths here: adjustable parameters; can optimize therapeutic window; can minimize adverse effects.
Relative tradeoffs: the abstract does not specify DRN targeting performance or insomnia efficacy for this modality; often relies on empirical outcomes due to undefined molecular targets; invasive.
Source:
The review contrasts DBS with focused ultrasound and gene therapy approaches such as AAV2-hAADC and ProSavin.
Source:
The abstract lists transcranial magnetic stimulation and focused ultrasound as other neuromodulation approaches, and also notes CBT-I and medications as standard treatments.
Source:
The review contrasts DBS with transcranial electrical and magnetic stimulation, focused ultrasound, chemogenetics, optogenetics, magnetogenetics, and toxin-based neuromodulation.
Source:
The review places DBS alongside optogenetics and non-invasive stimulation modalities such as photobiomodulation, electrical, ultrasound, and magnetic stimulation.
Ranked Citations
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
Extracted from this source document.
- 15.
- 16.